Metabolism and toxicity of drugs. Two decades of progress in industrial drug metabolism

被引:143
作者
Baillie, Thomas A. [1 ]
机构
[1] Merck Res Labs, Dept Drug Metab & Pharmacokinet, West Point, PA 19486 USA
关键词
D O I
10.1021/tx7002273
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The science of drug metabolism and pharmacokinetics (DMPK) has developed significantly over the past 20 years, and its functional role in today's pharmaceutical industry has matured to the point where DMPK has become an indispensable discipline in support of drug discovery and development. While contributions to the lead optimization phase of discovery efforts have been particularly noteworthy in helping to select only the best drug candidates for entry into development, it should be recognized that the scope of DMPK spans the continuum of discovery through clinical evaluation and even into the post-marketing phase; as such, the breadth of DMPK's involvement is almost unique in contemporary pharmaceutical research. This perspective summarizes notable advances in the field, many of which have been made possible by technological developments in areas such as molecular biology, genetics, and bioanalytical chemistry, and highlights the critical nature of key partnerships between Drug Metabolism, Medicinal Chemistry, and Safety Assessment groups in attempting to advance drug candidates with a low potential for causing adverse events in humans. Finally, some speculative predictions are made of the future role of DMPK in pharmaceutical research, where current advances in our mechanistic understanding of the molecular processes that control the absorption, disposition, metabolism, elimination, and toxicity of drugs and their biotransformation products will combine to further enhance the impact of DMPK in drug discovery and development.
引用
收藏
页码:129 / 137
页数:9
相关论文
共 79 条
  • [61] Untargeted analysis of mass spectrometry data for elucidation of metabolites and function of enzymes
    Sanchez-Ponce, Raymundo
    Guengerich, F. Peter
    [J]. ANALYTICAL CHEMISTRY, 2007, 79 (09) : 3355 - 3362
  • [62] Utility of the hybrid LTQ-FTMS for drug metabolism applications
    Sanders, Mark
    Shipkova, Petia A.
    Zhang, Haiying
    Warrack, Bethanne M.
    [J]. CURRENT DRUG METABOLISM, 2006, 7 (05) : 547 - 555
  • [63] Protein targets of reactive electrophiles in human liver microsomes
    Shin, Nah-Young
    Liu, Qinfeng
    Stamer, Sheryl L.
    Liebler, Daniel C.
    [J]. CHEMICAL RESEARCH IN TOXICOLOGY, 2007, 20 (06) : 859 - 867
  • [64] Seeing through the mist:: Abundance versus percentage.: Commentary on Metabolites in safety testing
    Smith, DA
    Obach, RS
    [J]. DRUG METABOLISM AND DISPOSITION, 2005, 33 (10) : 1409 - 1417
  • [65] Metabolites and safety: What are the concerns, and how should we address them?
    Smith, Dennis A.
    Obach, R. Scott
    [J]. CHEMICAL RESEARCH IN TOXICOLOGY, 2006, 19 (12) : 1570 - 1579
  • [66] Future of toxicology - Mechanisms of toxicity and drug safety: Where do we go from here?
    Stevens, James L.
    [J]. CHEMICAL RESEARCH IN TOXICOLOGY, 2006, 19 (11) : 1393 - 1401
  • [67] Utility of recombinant cytochrome P450 enzymes: A drug metabolism perspective
    Tang, W
    Wang, RW
    Lu, AYH
    [J]. CURRENT DRUG METABOLISM, 2005, 6 (05) : 503 - 517
  • [68] Idiosyncratic drug reactions: Current understanding
    Uetrecht, Jack
    [J]. ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 2007, 47 : 513 - 539
  • [69] Functional genomics of membrane transporters in human populations
    Urban, TJ
    Sebro, R
    Hurowitz, EH
    Leabman, MK
    Badagnani, I
    Lagpacan, LL
    Risch, N
    Giacomini, KM
    [J]. GENOME RESEARCH, 2006, 16 (02) : 223 - 230
  • [70] Nuclear receptors and the regulation of drug-metabolizing enzymes and drug transporters: Implications for interindividual variability in response to drugs
    Urquhart, Bradley L.
    Tirona, Rommel G.
    Kim, Richard B.
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2007, 47 (05) : 566 - 578